Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-part, Double-blind, Placebo-controlled, Phase I Study of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Intravenous VLX-1005 in Healthy Subjects

NCT04783545 is registered in ClinicalTrials.gov with Veralox Therapeutics as lead sponsor.

NCT NCT04783545
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04783545 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-part, Double-blind, Placebo-controlled, Phase I Study of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Intravenous VLX-1005 in Healthy Subjects
Lead sponsor
Veralox Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
March 24, 2021
Completion date
January 11, 2022
Enrollment
96 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

safety and tolerability in healthy volunteers